UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.43 Million Stake in Artivion, Inc. $AORT

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in Artivion, Inc. (NYSE:AORT) by 30.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,405 shares of the company’s stock after selling 27,372 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.13% of Artivion worth $1,425,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in AORT. Van ECK Associates Corp grew its holdings in shares of Artivion by 65.9% during the 2nd quarter. Van ECK Associates Corp now owns 10,749 shares of the company’s stock valued at $242,000 after purchasing an additional 4,269 shares during the last quarter. Wellington Management Group LLP increased its position in Artivion by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 1,260,279 shares of the company’s stock worth $28,318,000 after purchasing an additional 103,592 shares in the last quarter. Corient Private Wealth LP bought a new position in Artivion in the 2nd quarter valued at approximately $3,579,000. Bank of America Corp DE bought a new position in Artivion in the 2nd quarter valued at approximately $11,717,000. Finally, Freestone Grove Partners LP acquired a new stake in Artivion in the second quarter valued at approximately $328,000. Institutional investors own 86.37% of the company’s stock.

Artivion Trading Up 1.9%

Shares of NYSE AORT opened at $25.13 on Friday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25. The firm has a 50 day moving average price of $26.27 and a two-hundred day moving average price of $28.78. The stock has a market cap of $1.23 billion, a P/E ratio of -358.92 and a beta of 1.25.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The company had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. As a group, equities analysts forecast that Artivion, Inc. will post 0.45 EPS for the current year.

Insider Activity at Artivion

In related news, SVP Andrew Green sold 11,480 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $24.97, for a total transaction of $286,655.60. Following the completion of the transaction, the senior vice president directly owned 40,160 shares of the company’s stock, valued at $1,002,795.20. This trade represents a 22.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Jean Holloway sold 977 shares of Artivion stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares in the company, valued at $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 90,460 shares of company stock worth $2,557,366 over the last three months. Company insiders own 6.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AORT. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Canaccord Genuity Group raised their price objective on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Finally, Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $44.83.

Artivion Company Profile

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company’s portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.